A federal judge dismissed a move to block 340B cuts days before CMS’ final rule on it went into effect.
Days before CMS’ final rule on 340B went into effect, a federal judge dismissed a move to block the sharp cut to hospital reimbursements.
The American Hospital Association (AHA), America’s Essential Hospitals, and the Association of American Medical Colleges sued HHS last year to block the 2018 Medicare Outpatient Prospective Payment System rule that would cut $1.6 billion to the Medicare program. US District Judge Rudolph Contreras tossed the case, saying that the suit was premature since the changes hadn’t yet taken effect.
With the cuts now in effect as of January 1, 340B hospitals will receive smaller reimbursements for drugs purchased through the program. Under the old calculation, hospitals received 6% plus the average sales price of the drug; now, hospitals will receive the average sales price minus 22.5%. Rural sole community hospitals, certain cancer hospitals, and children’s hospital will be exempt from the reductions. According to CMS, the savings will be redistributed equally to hospitals covered under the rule. In addition to the cuts, 2 modifiers will be put in place in order to identify whether a drug was purchased under the 340B program.
“Making cuts to the program, like those [the CMS] has put forward, will dramatically threaten access to health care for many communities with vulnerable patients," said Rick Pollack, president and CEO, AHA, in a statement following the ruling. "We are disappointed in this decision from the court and will continue our efforts in the Courts and the Congress to reverse these significant cuts to the 340B program.”
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Combatting Misconceptions of Clinical Trials to Improve Patient Participation
October 16th 2024There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Read More
Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage
October 15th 2024Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Read More